Clinical Trials Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2015; 21(22): 6952-6964
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.6952
Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease
Nora Sipeki, Laszlo Davida, Eszter Palyu, Istvan Altorjay, Jolan Harsfalvi, Peter Antal Szalmas, Zoltan Szabo, Gabor Veres, Zakera Shums, Gary L Norman, Peter L Lakatos, Maria Papp
Nora Sipeki, Laszlo Davida, Eszter Palyu, Istvan Altorjay, Maria Papp, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Jolan Harsfalvi, Clinical Research Center, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Peter Antal Szalmas, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Zoltan Szabo, Division of Emergency Medicine, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Gabor Veres, Peter L Lakatos, 1st Department of Medicine, Semmelweis University, H-1083 Budapest, Hungary
Zakera Shums, Gary L Norman, Inova Diagnostics, Inc., San Diego, California, CA 92131, United States
Author contributions: Papp M, Lakatos PL, Antal Szalmas P, Szabo Z and Veres G designed research; Sipeki N, Papp M, Davida L, Palyu E and Altorjay I performed research; Harsfalvi J, Antal Szalmas P, Shums Z and Norman GL contributed new reagents/analytic tools; Papp M, Sipeki N and Lakatos PL analyzed data; Papp M, Sipeki N and Lakatos PL wrote paper.
Supported by Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences, Internal Research Grant of University of Debrecen and the IOIBD Research Grant.
Ethics approval: The study was reviewed and approved by the Hungarian National Review Board and the Institutional Review Board of the University of Debrecen.
Clinical trial registration: This registration policy applies to prospective, randomized, controlled trials only.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: Not declared.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maria Papp, MD, PhD, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary. papp.maria@med.unideb.hu
Telephone: +36-52-255152 Fax: +36-52-255152
Received: December 31, 2014
Peer-review started: January 4, 2015
First decision: February 10, 2015
Revised: March 1, 2015
Accepted: April 9, 2015
Article in press: April 9, 2015
Published online: June 14, 2015
Core Tip

Core tip: Enhanced serological antibody formation is a well-known feature of inflammatory bowel diseases. Antiphospholipid antibodies (APLAs) are a prothrombotic group of antibodies acquired in various inflammatory diseases. However their association with clinical phenotype and disease progression is still unclear in inflammatory bowel diseases (IBD). In the present study we report enhanced formation of APLAs in patients with Crohn’s disease, which was not associated with clinical phenotype or disease course during follow-up in a tertiary referral IBD center from Hungary.